Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
$99.99
$97.65
$45.50
$100.00
$6.17B0.551.56 million shs107 shs
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$9.07
+2.5%
$8.12
$5.20
$10.67
$1.23B1.161.40 million shs1.95 million shs
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$2.00
-1.0%
$2.03
$1.04
$3.73
$305.13M1.182.14 million shs861,287 shs
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
$47.99
$47.99
$19.64
$48.02
$2.27B1.051.16 million shs30,200 shs
Synthorx, Inc. stock logo
THOR
Synthorx
$67.99
$67.99
$11.05
$71.90
$2.20BN/A474,507 shsN/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
-1.56%+5.48%+8.72%+14.02%+52.59%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-0.98%-9.42%-0.49%+9.78%-44.96%
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Synthorx, Inc. stock logo
THOR
Synthorx
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
3.1754 of 5 stars
3.52.00.00.03.40.81.9
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.5539 of 5 stars
3.50.00.04.21.61.70.6
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Synthorx, Inc. stock logo
THOR
Synthorx
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
0.00
N/AN/AN/A
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$11.5026.79% Upside
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.00
Buy$5.00150.00% Upside
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
0.00
N/AN/AN/A
Synthorx, Inc. stock logo
THOR
Synthorx
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest HRTX, RARX, THOR, AUPH, and ARNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
$50K123,305.67N/AN/A$10.94 per share9.14
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$235.13M5.21$0.31 per share29.15$2.68 per share3.38
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$148.52M2.05N/AN/A($0.22) per share-9.09
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
$3M757.11N/AN/A$5.56 per share8.63
Synthorx, Inc. stock logo
THOR
Synthorx
N/AN/AN/AN/A$6.72 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
-$616.43M-$10.13N/AN/AN/AN/A-69.83%-62.35%N/A
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$5.75M$0.2832.3916.20N/A16.11%14.27%9.93%7/30/2025 (Estimated)
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$13.58M-$0.06N/AN/AN/A-5.24%N/A-3.43%8/5/2025 (Estimated)
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
-$102.69M-$2.31N/AN/AN/AN/A-44.61%-41.60%N/A
Synthorx, Inc. stock logo
THOR
Synthorx
-$56.61M-$6.59N/AN/AN/AN/A-26.09%-24.62%N/A

Latest HRTX, RARX, THOR, AUPH, and ARNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.18N/AN/AN/A$64.27 millionN/A
8/5/2025Q2 2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.01N/AN/AN/A$38.08 millionN/A
5/12/2025Q1 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.08$0.16+$0.08$0.16$61.06 million$62.47 million
5/6/2025Q1 2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.01$0.01+$0.02$0.01$37.08 million$38.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
N/AN/AN/AN/AN/A
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/AN/AN/AN/AN/A
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
N/AN/AN/AN/AN/A
Synthorx, Inc. stock logo
THOR
Synthorx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
0.05
8.59
8.59
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.16
5.93
5.26
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/A
2.40
1.76
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
0.01
14.78
14.79
Synthorx, Inc. stock logo
THOR
Synthorx
N/A
18.87
18.87

Institutional Ownership

CompanyInstitutional Ownership
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
83.77%
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
80.01%
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
N/A
Synthorx, Inc. stock logo
THOR
Synthorx
66.12%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
44861.66 million60.17 millionOptionable
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
300135.10 million118.62 millionOptionable
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
300152.56 million143.62 millionOptionable
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
7247.33 millionN/AOptionable
Synthorx, Inc. stock logo
THOR
Synthorx
4832.34 millionN/ANot Optionable

Recent News About These Companies

Pegenzileukin by Sanofi for Non-Small Cell Lung Cancer: Likelihood of Approval
Pegenzileukin by Sanofi for Squamous Cell Carcinoma: Likelihood of Approval
Biosimilar Interleukins Global Market Report 2023
Reed Reaches End Of The Road As Sanofi R&D Chief - Scrip

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arena Pharmaceuticals stock logo

Arena Pharmaceuticals NASDAQ:ARNA

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$9.07 +0.22 (+2.49%)
Closing price 04:00 PM Eastern
Extended Trading
$8.94 -0.13 (-1.38%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Heron Therapeutics stock logo

Heron Therapeutics NASDAQ:HRTX

$2.00 -0.02 (-0.99%)
Closing price 04:00 PM Eastern
Extended Trading
$2.00 +0.00 (+0.25%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Ra Pharmaceuticals stock logo

Ra Pharmaceuticals NASDAQ:RARX

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Synthorx stock logo

Synthorx NASDAQ:THOR

Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.